Advances in the Treatment of Malignant Gliomas

Local control with surgery, radiation, and temozolomide chemotherapy remain the pillars of treatment for high-grade gliomas. Novel therapeutic strategies, including a variety of antiangiogenic agents, are under investigation. One of these agents, bevacizumab, was recently given accelerated approval...

Full description

Saved in:
Bibliographic Details
Published inCurrent oncology reports Vol. 12; no. 1; pp. 26 - 33
Main Authors Khasraw, Mustafa, Lassman, Andrew B.
Format Journal Article
LanguageEnglish
Published New York Current Science Inc 2010
Subjects
Antineoplastic Agents - therapeutic use
Brain Neoplasms - drug therapy
Glioma - drug therapy
Humans
Medicine
Medicine & Public Health
Oncology
Temozolomide
Antiangiogenic therapy
Glioblastoma
Bevacizumab
Online AccessGet full text

Cover

More Information
Summary:Local control with surgery, radiation, and temozolomide chemotherapy remain the pillars of treatment for high-grade gliomas. Novel therapeutic strategies, including a variety of antiangiogenic agents, are under investigation. One of these agents, bevacizumab, was recently given accelerated approval by the US Food and Drug Administration as a single agent for recurrent glioblastoma. Recent trial results are generating important clinical questions regarding which patients to treat and when, and how best to monitor response. Encouraging results of recent studies are driving willingness to undertake aggressive treatment and to improve outcomes in this population. In this era, better understanding of biology, molecular aspects of cancer, and clinical trial methodology are crucial for clinicians. This review focuses on recent advances in the treatment malignant gliomas, especially antiangiogenic therapy.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1523-3790
1534-6269
DOI:10.1007/s11912-009-0077-4